Trump Plans to Impose 100% Tariffs on Generic Drugs Starting in 2028. What Would That Do to Prices?

Time | Chantelle Lee

U.S. President Donald Trump announced plans to impose a 100% tariff on imported generic drugs starting in August 2028, escalating to 200% after one year to force pharmaceutical companies to reshore manufacturing to America. This aggressive trade policy aims to protect domestic consumers but risks triggering severe medication shortages and driving up healthcare costs.

Currently, the American healthcare system relies heavily on foreign suppliers, with India providing approximately half of all generic medications and China supplying 80% of the active pharmaceutical ingredients used by Indian manufacturers. Industry experts warn that while generic drugs make up over 90% of prescriptions filled domestically, sudden tariffs could compel manufacturers to abandon the U.S. market entirely. Although the Food and Drug Administration notes generics are significantly cheaper than brand-name alternatives, doubling their prices would exacerbate existing affordability crises for the nearly 50% of American adults struggling with healthcare costs.

Comment

The proposed tariff structure exposes the deep systemic vulnerabilities of the American pharmaceutical supply chain, which relies on the U.S. Food and Drug Administration to regulate a market heavily dependent on foreign active pharmaceutical ingredients. Attempting to reshore generic drug manufacturing to domestic facilities within a tight four-year window overlooks the capital-intensive nature of chemical synthesis plants. Consequently, sudden trade barriers on imports from major hubs like Gujarat or Zhejiang risk triggering severe domestic shortages of critical therapies before American manufacturing infrastructure can achieve operational scale.

To read in details click here